tiprankstipranks
Trending News
More News >
Pharma Foods International Co., Ltd. (JP:2929)
:2929
Japanese Market
Advertisement

Pharma Foods International Co., Ltd. (2929) AI Stock Analysis

Compare
1 Followers

Top Page

JP

Pharma Foods International Co., Ltd.

(2929)

Rating:54Neutral
Price Target:
¥831.00
▼(-1.42%Downside)
Pharma Foods International Co., Ltd. faces significant challenges. The most impactful factor is the bearish technical outlook, indicating potential further downside. Financial performance shows strong operational efficiency but is offset by high leverage and cash flow concerns, while high valuation raises caution. The absence of earnings call data and corporate events limits further insights.

Pharma Foods International Co., Ltd. (2929) vs. iShares MSCI Japan ETF (EWJ)

Pharma Foods International Co., Ltd. Business Overview & Revenue Model

Company DescriptionPharma Foods International Co., Ltd. engages in the development and sale of functional food ingredients in Japan. Its products include Pharma-GABA, Bonepep, Ovopron (egg yolk globulin), Delicious Catechin, RunPep, and enriched Folic Acid Egg, as well as iHA, a substance that stimulates secretion of hyaluronic acid. Pharma Foods International Co., Ltd. has licensing agreement with Mitsubishi Tanabe Pharma Corporation for a new therapeutic antibody to treat autoimmune diseases. Pharma Foods International Co., Ltd. was founded in 1997 and is based in Kyoto, Japan.
How the Company Makes MoneyPharma Foods International Co., Ltd. generates revenue through the sale of its functional food ingredients, supplements, and pharmaceutical products. The company targets various markets, including the health-conscious consumer segment and the pharmaceutical industry. Key revenue streams include product sales to food manufacturers, direct sales of supplements to consumers, and partnerships with pharmaceutical companies for the development and distribution of healthcare products. Strategic collaborations and licensing agreements also contribute to its earnings, allowing the company to leverage external expertise and expand its market reach.

Pharma Foods International Co., Ltd. Financial Statement Overview

Summary
Pharma Foods International Co., Ltd. demonstrates strong profitability and efficiency, with a solid gross profit margin. However, it faces challenges with declining net profit margins and volatile revenue growth. The balance sheet is stable but highly leveraged, and cash flow issues highlight liquidity concerns.
Income Statement
72
Positive
Pharma Foods International Co., Ltd. has shown consistent growth with a strong gross profit margin of 79.4% in TTM, indicating excellent cost management. However, the net profit margin decreased to 4.4% from 5.2% annually, suggesting pressure on profitability. The revenue growth rate has been volatile, with a decline in the recent TTM period. EBIT and EBITDA margins are robust at 7% and 8.6%, respectively, but the decline from previous years highlights potential operational challenges.
Balance Sheet
68
Positive
The company's balance sheet reflects a stable equity ratio of 36.5% in TTM, indicating a solid financial foundation. However, the debt-to-equity ratio is high at 1.03, suggesting significant leverage. Return on equity has improved to 22.1%, showcasing stronger profitability relative to equity, yet the high leverage presents financial risk.
Cash Flow
58
Neutral
The cash flow situation is concerning, with a negative free cash flow in the TTM period. The operating cash flow to net income ratio is low at 0.007, indicating weak cash generation from operations relative to net income. Free cash flow has seen a steep decline, pointing to liquidity challenges.
BreakdownSep 2024Sep 2023Sep 2022Sep 2021Sep 2020
Income Statement
Total Revenue62.15B68.57B60.19B46.75B15.35B
Gross Profit48.75B55.28B48.11B39.73B12.18B
EBITDA6.00B4.16B1.60B5.86B1.01B
Net Income3.21B3.08B-374.00M3.84B690.00M
Balance Sheet
Total Assets36.57B36.23B31.16B20.94B10.10B
Cash, Cash Equivalents and Short-Term Investments15.67B16.31B8.85B9.79B3.28B
Total Debt16.89B20.10B16.86B4.90B3.58B
Total Liabilities24.99B26.60B24.09B12.48B5.19B
Stockholders Equity11.59B9.63B7.07B8.46B4.91B
Cash Flow
Free Cash Flow4.51B5.72B-6.54B5.76B-1.46B
Operating Cash Flow5.49B6.13B-6.07B5.94B-547.06M
Investing Cash Flow-1.39B-1.01B-2.54B-442.00M-860.93M
Financing Cash Flow-4.84B2.34B7.68B1.03B375.63M

Pharma Foods International Co., Ltd. Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price843.00
Price Trends
50DMA
900.06
Negative
100DMA
891.02
Negative
200DMA
912.52
Negative
Market Momentum
MACD
-18.83
Negative
RSI
46.34
Neutral
STOCH
49.70
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:2929, the sentiment is Neutral. The current price of 843 is above the 20-day moving average (MA) of 834.30, below the 50-day MA of 900.06, and below the 200-day MA of 912.52, indicating a neutral trend. The MACD of -18.83 indicates Negative momentum. The RSI at 46.34 is Neutral, neither overbought nor oversold. The STOCH value of 49.70 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:2929.

Pharma Foods International Co., Ltd. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (60)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
74
Outperform
€32.57B10.237.01%3.00%13.46%-46.40%
68
Neutral
¥34.61B18.34
3.04%8.07%-45.20%
65
Neutral
¥18.51B6.46
3.98%9.31%-340.82%
60
Neutral
HK$16.12B5.55-7.44%3.87%11.55%-28.15%
54
Neutral
¥24.42B85.86
2.96%-2.24%-92.72%
50
Neutral
¥10.03B155.65
1.04%0.66%-40.86%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
JP:2929
Pharma Foods International Co., Ltd.
843.00
-176.25
-17.29%
JP:4512
Wakamoto Pharmaceutical Co., Ltd.
291.00
40.31
16.08%
JP:4538
Fuso Pharmaceutical Industries,Ltd.
2,124.00
-178.76
-7.76%
JP:4577
Daito Pharmaceutical Co., Ltd.
1,144.00
34.16
3.08%
JP:4554
Fuji Pharma Co., Ltd.
1,350.00
-152.93
-10.18%

Pharma Foods International Co., Ltd. Corporate Events

Pharma Foods International Expands with New Manufacturing Facility
Jun 16, 2025

Pharma Foods International Co., Ltd. has announced the construction of a new manufacturing facility for its subsidiary, Meiji Yakuhin Co., Ltd., as part of its strategy to become a leading healthcare company. This investment, amounting to JPY 12.5 billion, aims to boost production capacity and expand the sales of Meiji Yakuhin’s own-brand products, targeting net sales of JPY 23 billion by 2030. The move is expected to enhance the company’s market position and address common healthcare needs, contributing significantly to its growth and vision.

Pharma Foods Reports Nine-Month Financial Results with Recovery Forecast
Jun 10, 2025

Pharma Foods International Co., Ltd. reported a slight decline in net sales for the nine months ending April 30, 2025, with a decrease of 0.8% compared to the previous year. The company experienced a loss in operating and ordinary profit, as well as a negative profit attributable to owners of the parent. Despite these challenges, the company forecasts a recovery in the fiscal year ending July 31, 2025, with expected increases in net sales and profits, although at lower growth rates compared to the previous year.

Pharma Foods International Executes Share Repurchase Strategy
May 14, 2025

Pharma Foods International Co., Ltd. has repurchased 184,600 of its own common shares through the Tokyo Stock Exchange’s off-auction trading system, ToSTNeT-3, at a cost of ¥175,370,000. This move is part of the company’s strategy to enhance capital efficiency, return capital to shareholders, and support equity-based compensation, reflecting its commitment to optimizing shareholder value.

Pharma Foods International Announces Share Repurchase Program
May 13, 2025

Pharma Foods International Co., Ltd. has announced a share repurchase program, approved by its Board of Directors, to acquire up to 200,000 common shares at a maximum cost of ¥190,000,000. This initiative aims to enhance capital efficiency, provide equity-based compensation, and return capital to shareholders, reflecting a strategic move to optimize shareholder value.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 03, 2025